Replimune Group (NASDAQ:REPL) CFO Sells $132,175.68 in Stock

Replimune Group, Inc. (NASDAQ:REPL) CFO Emily Luisa Hill sold 9,256 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $14.28, for a total transaction of $132,175.68. Following the transaction, the chief financial officer owned 215,852 shares of the company’s stock, valued at approximately $3,082,366.56. This trade represents a 4.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Emily Luisa Hill also recently made the following trade(s):

• On Monday, August 10th, Emily Luisa Hill sold 11,448 shares of Replimune Group stock. The shares were sold at an average price of $12.97, for a total transaction of $148,480.56.

Replimune Group Price Performance

REPL stock traded down $0.77 during trading on Wednesday, hitting $14.81. The stock had a trading volume of 3,436,495 shares, compared to its average volume of 4,981,821. Replimune Group, Inc. has a twelve month low of $1.50 and a twelve month high of $15.70. The company’s 50-day moving average price is $10.90 and its two-hundred day moving average price is $7.90. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79. The stock has a market capitalization of $1.24 billion, a P/E ratio of -4.70 and a beta of 0.88.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). As a group, research analysts predict that Replimune Group, Inc. will post -2.78 EPS for the current fiscal year.

Key Stories Impacting Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Replimune announced inducement equity awards for Chief Commercial Officer Michelle DiNapoli under Nasdaq Listing Rule 5635(c)(4). The grants are intended to support employee recruitment and retention, but will modestly increase potential share dilution. Replimune Announces Inducement Grants
• Neutral Sentiment: CFO Emily Luisa Hill sold 9,256 shares for approximately $132,176 at an average price of $14.28. The filing states the sale was made to cover tax-withholding obligations tied to vested equity awards; she continues to own 215,852 shares, reducing the signal of discretionary insider selling. SEC Insider Transaction Filing
• Negative Sentiment: Several law firms publicized the securities class action and reminded investors of the October 5, 2026 deadline to seek lead-plaintiff status. The complaints allege Replimune’s filings did not adequately disclose that FDA concerns about the RP1 study design remained unresolved. Although the allegations have not been proven, the legal uncertainty creates an overhang and could increase potential costs or liabilities. Replimune Securities Fraud Lawsuit Deadline Alert

Analysts Set New Price Targets

REPL has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 23rd. JPMorgan Chase & Co. upped their price objective on shares of Replimune Group from $17.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Finally, Weiss Ratings lowered shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Replimune Group presently has a consensus rating of “Moderate Buy” and an average price target of $11.86.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. ProShare Advisors LLC grew its position in Replimune Group by 10.3% in the 4th quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock valued at $157,000 after acquiring an additional 1,505 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Replimune Group by 4.7% during the third quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock worth $159,000 after purchasing an additional 1,712 shares in the last quarter. Ballentine Partners LLC boosted its stake in shares of Replimune Group by 7.8% in the fourth quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock valued at $230,000 after purchasing an additional 1,721 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after purchasing an additional 1,879 shares during the period. Finally, Walleye Capital LLC grew its holdings in shares of Replimune Group by 3.2% in the first quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock valued at $548,000 after purchasing an additional 2,192 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.